Design efficiency in dose finding studies

DOI10.1016/S0167-9473(02)00323-7MaRDI QIDQ956828zbMATH OpenOpenAlexFDO

Authors Xavier Paoletti, John O'Quigley, Jean Maccario

Publication date 26 November 2008

Published in Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/s0167-9473(02)00323-7

zbMATH Keywords

clinical trialsdose findingefficiencyoptimalityphase I designs

Mathematics Subject Classification ID

Sequential statistical design (62L05) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Optimal designs for dose-finding studies
• Optimal designs for dose finding studies with an active control
• Dose Finding – A Challenge in Statistics
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint

Cites work

• A Curve‐Free Method for Phase I Clinical Trials
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• scientific article; zbMATH DE number 524373 (Why is no real title available?)
• Miscellanea. A stopping rule for the continual reassessment method
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• Non-parametric optimal design in dose finding studies
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Cited in

(26)

• Adaptive clinical trial designs for phase I cancer studies
• Cumulative cohort design for dose-finding
• Up-and-down designs for dose-finding
• Prediction Approaches to Sequentially Searching for an Optimal Dose
• Coherence principles in dose-finding studies
• Efficiency of bridging between related dose finding studies
• Adaptive Bayesian compound designs for dose finding studies
• Robustness of Design in Dose–Response Studies
• Biometric practicesimple benchmark for complex dose finding studies
• Non-parametric optimal design in dose finding studies
• Optimal designs for dose finding studies with an active control
• Target toxicity design for phase I dose-finding
• Performance Measures in Dose‐Finding Experiments
• A modified Huber loss function for continual reassessment methods in clinical trials
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
• Patient retreat in dose escalation for phase I clinical trials with rare diseases
• Dose finding with longitudinal data: simpler models, richer outcomes
• Phase I design for completely or partially ordered treatment schedules
• STEIN: a simple toxicity and efficacy interval design for seamless phase I/II clinical trials
• Performance of toxicity probability interval based designs in contrast to the continual reassessment method
• Designs for phase I trials in ordered groups
• Implementation of adaptive methods in early-phase clinical trials
• BAR12: Bayesian autoregressive phase 1-2 design for cell therapy trials with manufacturing changes
• Continual reassessment and related dose-finding designs

This page was built for publication: Design efficiency in dose finding studies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q956828)